ÖZETAmaç: Heparin analoglarının düşük dozlarının antiproliferatif ve immünmodülatör etkilerinin olduğu bilinmektedir. Bu çalışmanın amacı; liken planusta düşük doz enoxaparinin etkinliğini değerlendirmektir.
Gereç ve yöntem:Liken planus tanısı alan 21 hasta 12 hafta boyunca tedavi edildi. Hastalara her hafta 3 mg enoxaparin subkutan enjeksiyonla yapıldı. Etki ve güven-lik verileri kaydedildi.
Bulgular:Tam iyileşme hastaların 15' inde (%71), belirgin düzelme 4' ünde (%19) tespit edildi. Hastaların 2'sinde (%9) tedaviye yanıt alınmadı. Tedavi sonucunda en iyi yanıt, liken planusun akut generalize tipinde görüldü.Sonuç: Sonuç olarak enoxaparin tedavisinin liken planusta etkili bir tedavi seçeneği olabileceği kanaatine varıldı.Anahtar kelimeler: Liken planus, enoxaparin, tedavi ABSTRACT Objectives: As it is known, the low doses of Heparin's analogues have the antiproliferative and immunomodulator activities. This research aims to evaluate the activity of enoxaparin by using the low doses.
Materials and methods:21 patients with lichen planus diagnosis have been cured within 12 weeks. 3 mg of enoxaparin has been used for subcutaneus injection to all of patients weekly. The efficient and reliable data has been saved.
Results:The perfect recovery has been observed 15 (71%) of 21 patients, the distinct recovery has been observed 4 (19%) of 21 patients. The treatment has not given response on 2 (9%) of 21 patients. The best score has been received on acute generalized type of Lichen Planus.
Conclusions:As the result; it has been reported that enoxaparin treatment can be an effective choice in Lichen Planus medication. J Clin Exp Invest 2011; 3(2): 172-173
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.